Colonisation by <i><scp>F</scp>aecalibacterium prausnitzii</i> and maintenance of clinical remission in patients with ulcerative colitis

Varela, Encarnación; Manichanh, Chaysavanh; Gallart, Milagros; Torrejón, Antonio; Borruel, Natalia; Casellas, Francesc; Guarner, Francisco; Antolı́n, Maria

doi:10.1111/apt.12365

Cited by 201 publications

(112 citation statements)

References 35 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Low abundance of these genera is associated with increased disease activity in IBD. [21][22][23] As Clostridium species have been found to induce the expansion of regulatory T cells, 24 it is tempting to speculate that depletion of these taxa may reduce the number of regulatory T cells, which may play a role in SSc pathogenesis. 25 It is important to note, however, that species within this genus vary in terms of their metabolic properties.…”

Section: Discussionmentioning

confidence: 99%

Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts

Volkmann

Hoffmann‐Vold

Chang

et al. 2017

BMJ Open Gastroenterol

View full text Add to dashboard Cite

ObjectiveTo compare faecal microbial composition in patients with systemic sclerosis (SSc) from 2 independent cohorts with controls and to determine whether certain genera are associated with SSc-gastrointestinal tract (GIT) symptoms.DesignAdult patients with SSc from the University of California, Los Angeles (UCLA) and Oslo University Hospital (OUH) and healthy controls participated in this study (1:1:1). All participants provided stool specimens for 16S rRNA sequencing. Linear discriminant analysis effect size demonstrated genera with differential expression in SSc. Differential expression analysis for sequence count data identified specific genera associated with GIT symptoms as assessed by the GIT 2.0 questionnaire.ResultsThe UCLA-SSc and OUH-SSc cohorts were similar in age (52.1 and 60.5 years, respectively), disease duration (median (IQR): 6.6 (2.5–16.4) and 7.0 (1.0–19.2) years, respectively), gender distribution (88% and 71%, respectively), and GIT symptoms (mean (SD) total GIT 2.0 scores of 0.7 (0.6) and 0.6 (0.5), respectively). Principal coordinate analysis illustrated significant microbial community differences between SSc and controls (UCLA: p=0.001; OUH: p=0.002). Patients with SSc had significantly lower levels of commensal genera deemed to protect against inflammation, such as Bacteroides (UCLA and OUH), Faecalibacterium (UCLA), Clostridium (OUH); and significantly higher levels of pathobiont genera, such as Fusobacterium (UCLA), compared with controls. Increased abundance of Clostridium was associated with less severe GIT symptoms in both cohorts.ConclusionsThe present analysis detected specific aberrations in the lower GIT microbiota of patients with SSc from 2 geographically and ethnically distinct cohorts. These findings suggest that GIT dysbiosis may be a pathological feature of the SSc disease state.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts

Volkmann

Hoffmann‐Vold

Chang

et al. 2017

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…78 Conversely, recovery of F. prausnitzii after relapse is associated with maintenance of clinical remission of UC. 81 …”

Section: Protective Effects Of Microbes In Ibdmentioning

confidence: 99%

The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead

2014

View full text Add to dashboard Cite

Studies of the roles of microbial communities in the development of inflammatory bowel diseases (IBD) have reached an important milestone. A decade of genome-wide association studies and other genetic analyses have linked IBD with loci that implicate an aberrant immune response to the intestinal microbiota. More recently, profiling studies of the intestinal microbiome have associated pathogenesis of IBD with characteristic shifts in the composition of the intestinal microbiota, reinforcing the view that IBD results from altered interactions between intestinal microbes and the mucosal immune system. Enhanced technologies can increase our understanding of the interactions between the host and its resident microbiota, and their respective roles in IBD, from both a large-scale pathway view and at the metabolic level. We review important microbiome studies of patients with IBD and describe what we have learned about the mechanisms of intestinal microbiota dysfunction. We describe the recent progress in microbiome research from exploratory 16S-based studies, reporting associations of specific organisms with a disease, to more recent studies that have taken a more nuanced view, addressing the function of the microbiota by metagenomic and metabolomic methods. Finally, we propose study designs and methodologies for future investigations of the microbiome in patients with inflammatory gut and autoimmune diseases in general.

show abstract

“…Over the past 5 years, an increasing number of studies have clearly described the importance of this highly metabolically active commensal bacterium as a component of the healthy human microbiota. Changes in the abundance of F. prausnitzii have been linked to dysbiosis in several human disorders, including ulcerative colitis [50], CD [51,52], and multiple sclerosis [9]. F. prausnitzii is one of the most abundant butyrate-producing bacteria in the gastrointestinal tract.…”

Section: Dysbiosis Induced By Ppismentioning

confidence: 99%

Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use

Naito

Kashiwagi²,

Takagi³

et al. 2018

Digestion

View full text Add to dashboard Cite

Background: Gut dysbiosis associated with the use of proton-pump inhibitors (PPIs) has been found to lead to the occurrence of infectious and inflammatory adverse events. A longitudinal observational cohort study has demonstrated the heightened risk of death associated with PPI use. Summary: We evaluated meta-analyses to determine the association between PPI use and infectious and inflammatory diseases. Meta-analyses showed that PPI use is a potential risk for the development of enteric infections caused by Clostridium difficile, as well as small intestinal bacterial overgrowth, spontaneous bacterial peritonitis, community-acquired pneumonia, hepatic encephalopathy, and adverse outcomes in inflammatory bowel disease. We also examined changes in the composition and function of the gut microbiota with the use of PPIs. PPI use significantly increased the presence of Streptococcaceae and Enterococcaceae, which are risk factors for C. difficile infection, and decreased that of Faecalibacterium, a commensal anti-inflammatory microorganism. Key Message: High-throughput, microbial 16S rRNA gene sequencing has allowed us to investigate the association between the gut microbiome and PPI use. Future prospective comparison studies are necessary to confirm this association, and to develop new strategies to prevent complications of PPI use

show abstract

Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis

Cited by 201 publications

References 35 publications

Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts

Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts

The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead

Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use

Contact Info

Product

Resources

About